Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.
|Original language||English (US)|
|Number of pages||4|
|Journal||Nouvelle Revue Francaise d'Hematologie|
|State||Published - Jan 1 1982|
ASJC Scopus subject areas